Call for proposals to support the development of a medicine pricing, reimbursement and access tracker through the EURIPID database
Programme Category
Programme Name
Programme Description
The Programme aims to improve and promote health in the Union to reduce the burden of communicable and non-communicable diseases by:
- protecting people from serious cross-border health threats
- improving the availability, accessibility and affordability of medicines, medical devices and other crisis-related products in the EU
- strengthening national health systems
Identifier Code
Call
Summary
In the short term, this action will provide EURIPID members with a better overview of access, P&R measures and decisions across the Member States.
In the longer term, it is expected to support mutual learning between national authorities and help the Member States in taking better pricing and reimbursement decisions, with a view to improve access, availability, and affordability of medicines. This is in line with the recommendations in the Draghi Report on the future of European competitiveness, and with the priority to ensure supply of affordable medicines, as outlined in the mission letter from Commission President von der Leyen to the Commissioner for Health and Animal Welfare.
The proposed “pricing and reimbursement (‘P&R’) tracker” and access dashboard will allow improved monitoring of patients’ access to medicines across the Union, including for cancer treatments. Having this data available prior to the application of the proposed pharmaceutical reform, will serve to measure the baseline and subsequently the impact of the proposed measures that aim to increase access to medicines across the Union, including for cancer treatments.
Detailed Call Description
The scope of this action is to develop through the EURIPID database:
a) a “pricing and reimbursement (‘P&R’) tracker”, including national information on early access schemes; P&R applications, status, decision; and P&R criteria or conditions (general and product-specific);
b) access dashboards, building on OECD indicators, including on availability (e.g., coverage status, time-to-reimbursement), affordability (e.g., cost of treatment), accessibility (e.g., consumption/uptake);
c) an annual trend analysis report of access to medicines in the Union;
d) solutions that can facilitate data sharing with EURIPID, such as automatization using application programming interface and machine-machine interaction with each Member State;
e) reinforced interoperability of EURIPID with other existing databases (e.g. the European Shortages Medicine Platform, Substance, Product, Organisation and Referential master data, Product Management Service, etc.) and integrating data assets in the European Health Data Space.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
Indicative project budget: €750.000
The costs will be reimbursed at the funding rate fixed in the Grant Agreement (60%).
You can apply for a higher project funding rate (80%) if your project is of ‘exceptional utility’, i.e. concerns:
- actions where at least 30 % of the budget is allocated to Member States (or EU4H associated countries) whose GNI per inhabitant is less than 90% of the EU average or
- actions with bodies from at least 14 Member States (or EU4H associated countries) and where at least four are from Member States (or EU4H associated countries) whose GNI per inhabitant is less than 90% of the EU average.
Grants may NOT produce a profit (i.e. surplus of revenues + EU grant over costs).
For-profit organisations must declare their revenues and, if there is a profit, we will deduct it from the final grant amount.
Thematic Categories
- Health
Eligibility for Participation
- Businesses
- Educational Institutions
- Large Enterprises
- Legal Entities
- NGOs
- Non Profit Organisations
- Private Bodies
- Researchers/Research Centers/Institutions
- Semi-governmental organisations
- Small and Medium Enterprises (SMEs)
- State-owned Enterprises
Eligibility For Participation Notes
In order to be eligible, the applicants (beneficiaries and affiliated entities) must be legal entities (public or private bodies) established in EU Member States (including overseas countries and territories (OCTs)) or EEA countries and countries associated to the EU4Health Programme (list of participating countries).
For topic EU4H-2026-SANTE-PJ-06: Proposals must be submitted by a consortium which complies with the following conditions:
- at least 4 beneficiaries from 3 different eligible countries.
- applicants should be EURIPID members, public authorities on pricing and reimbursement of medicines.
Type of applicants targeted: Authorities competent in the domain of pricing and reimbursement of medicines from the Member States being members of EURIPID
Call Opening Date
Call Closing Date
National Contact Point(s)
Ministry of Health, Department of European Affairs
Telephone: 22605300/301, 22605617, 22605718
Address: Corner of Prodromou 1 & Chilonos 17 1448 Nicosia, Cyprus
Ms MAKRIGIORGI Elena
Email: emakrigiorgi@moh.gov.cy